#PAGE_PARAMS# #ADS_HEAD_SCRIPTS# #MICRODATA#

Adipocytokines as possible etiopathogenetic mechanisms leading to a higher incidence of autoimmune thyroiditis in patients with type 2 diabetes mellitus


Authors: Štefan Sotak 1;  Zbynek Schroner 2;  Ivica Lazúrová 1;  Marek Felš Ci 1;  Darina Petrášová 3;  Izabela Bertková 4;  Miriam Mitníková 5;  Jozefína Petrovičová 6
Authors‘ workplace: I. interná klinika LF UPJŠ a UNLP Košice 1;  IV. interná klinika LF UPJŠ a UNLP Košice 2;  Laboratórium výskumných biomodelov LF UPJŠ v Košiciach 3;  Ústav experimentálnej medicíny LF UPJŠ v Košiciach 4;  Oddelenie laboratórnej medicíny UNLP Košice 5;  Ústav lekárskej informatiky LF UPJŠ v Košiciach 6
Published in: Diab Obez 2019; 19(38): 103-109
Category: Reviews

Overview

Introduction: Autoimmune thyroiditis (AIT) and type 2 diabetes mellitus (DM) are the most common endocrinological diseases worldwide. Relationship between type 1 DM and AIT is well-known and described. Relation between these diseases explains several hypotheses. One of them is influence of some adipocytokines.

Objective: This study evaluated relationship between three adipocytokines (adiponectin, resistin, visfatin) and thyroidal status in patients with type 2 DM and AIT compared to control group (CG).

Material and methods: The group consisted of four subgroups: patients with type 2 DM without thyreopathies (n = 45), patients with AIT on substitution therapy without diabetes and prediabetes (n = 37), patients with type 2 DM and AIT on substitution therapy (n = 28) and healthy subjects as a CG (n = 34). We investigated parameters of thyroid and glycid metabolism and levels of three adipocytokines by venous blood-letting.

Results: We did not find statistically significant differences of adiponectine, resistin and visfatin levels between individual groups. We found moderate negative correlation between visfatin and fasting glucose levels (r = -0.35, p = 0.03) in patients with AIT without type 2. Conclusion: Our results are consistent with several studies, which do not find any relationship between thyropathies and adipocytokines.

Keywords:

adipocytokines – Adiponectin – autoimmune thyroiditis – resistin – type 2 diabetes mellitus – visfatin


Sources
  1. Schroner Z, Lazúrová I, Petrovičová J. Autoimmune thyroid diseases in patients with diabetes mellitus. Bratisl Lek Listy 2008; 109(3): 125–129.
  2. Kresser C. The Role of Vitamin D Deficiency in Thyroid Disorders 2010. [online]. [cit 20–04–2015]. Dostupné z www: <http://chriskresser.com/the-role-of-vitamin-d-deficiency-in-thyroid-disorders/>.
  3. Itariu BK, Stulnig TM. Autoimmune Aspects of Type 2 Diabetes Mellitus – A Mini Review. Gerontology 2014; 60(3): 189–196. Dostupné z DOI: <http://dx.doi.org/10.1159/000356747>.
  4. Gierach M, Gierach J, Skowrońska A et al. Hashimoto’s thyroiditis and carbohydrate metabolism disorders in patients hospitalized in the Department of Endocrinology and Diabetology of Ludwik Rydygier Collegium Medicum in Bydgoszcz between 2001 and 2010. Endokrynol Pol 2012; 63(1): 14–17.
  5. Cinar N, Gurlek A. Association between novel adipocytokines adiponectin, vaspin, visfatin, and thyroid: An experimental and clinical update. Endocr Connect 2013; 2(4): R30-R38. Dostupné z DOI: <http://dx.doi.org/10.1530/EC-13–0061>.
  6. Misra A, Vikram NK. Clinical and pathophysiological consequences of abdominal adiposity and abdominal adipose tissue depots. Nutrition 2003; 19(5): 457–466. Dostupné z DOI: <http://dx.doi.org/10.1016/s0899–9007(02)01003–1>.
  7. Ahima RS, Qi Y, Singhal NS et al. Brain adipocytokine action and metabolic regulation. Diabetes 2006; 5(Suppl 2): S145-S154. Dostupné z DOI: <http://dx.doi.org/10.2337/db06-s018>.
  8. Fernández-Real JM, López-Bermejo A, Casamitjana R et al. Novel interactions of adiponectin with the endocrine system and inflammatory parameters. J Clin Endocrinol Metab 2003; 88(6): 2714–2718. Dostupné z DOI: <http://dx.doi.org/10.1210/jc.2002–021583>.
  9. Cabanelas A, Cordeiro A, Santos Almeida NA et al. Effect of triiodothyronine on adiponectin expression and leptin release by white adipose tissue of normal rats. Horm Metab Res 2010; 42(4): 254–260. Dostupné z DOI: <http://dx.doi.org/10.1055/s-0029–1246118>.
  10. Stumvoll M, Häring H. Resistin and Adiponectin – of Mice and Men. Obes Res 2002; 10(11): 1197–1199. Dostupné z DOI: <http://dx.doi.org/10.1038/oby.2002.162>.
  11. Nogueiras R, Gualillo O, Caminos JE et al. Regulation of resistin by gonadal, thyroid hormone, and nutritional status. Obes Res 2003; 11(3): 408–414. Dostupné z DOI: <http://dx.doi.org/10.1038/oby.2003.55>.
  12. Samal B, Sun Y, Stearns G et al. Cloning and characterization of the cDNA encoding a novel human pre-B-cell colony-enhancing factor. Mol Cell Biol 1994; 14(2): 1431–1437. Dostupné z DOI: <http://dx.doi.org/10.1128/mcb.14.2.1431>.
  13. Moschen AR, Kaser A, Enrich B et al. Visfatin, an adipocytokine with proinflammatory and immunomodulating properties. J Immunol 2007; 178(3): 1748–1758. Dostupné z DOI: <http://dx.doi.org/10.4049/jimmunol.178.3.1748>.
  14. Iglesias P, Alvarez Fidalgo P, Codoceo R et al. Serum concentrations of adipocytokines in patients with hyperthyroidism and hypothyroidism before and after control of thyroid function. Clin Endocrinol (Oxf) 2003; 59(5): 621–629. Dostupné z DOI: <http://dx.doi.org/10.1046/j.1365–2265.2003.01897.x>.
  15. Santini F, Marsili A, Mammoli C et al. Serum concentrations of adiponectin and leptin in patients with thyroid dysfunctions. J Endocrinol Invest 2004; 27(2):RC5–7. Dostupné z DOI: <http://doi 10.1007/BF03346252>.
  16. Altinova AE, Törüner FB, Aktürk M et al. Adiponectin levels and cardiovascular risk factors in hypothyroidism and hyperthyroidism. Clin Endocrinol (Oxf) 2006; 65(4): 530–535. Dostupné z DOI: <http://dx.doi.org/10.1111/j.1365–2265.2006.02628.x>.
  17. Iglesias P, Díez JJ. Influence of thyroid dysfunction on serum concentrations of adipocytokines. Cytokine 2007; 40(2): 61–70. Dostupné z DOI: <http://dx.doi.org/10.1016/j.cyto.2007.10.001>.
  18. Siemińska L, Wojciechowska C, Kos-Kudła B et al. Serum concentrations of leptin, adiponectin, and interleukin-6 in postmenopausal women with Hashimoto’s thyroiditis. Endokrynol Pol 2010; 61(1): 112–116.
  19. Kaplan O, Uzum AK, Aral H et al. Unchanged serum adipokine concentrations in the setting of short-term thyroidectomy-induced hypothyroidism. Endocr Pract 2012; 18(6): 887–893. Dostupné z DOI: <http://dx.doi.org/10.4158/EP12001.OR>.
  20. Yildiz BO, Aksoy DY, Harmanci A et al. Effects of L-thyroxine therapy on circulating leptin and adiponectin levels in subclinical hypothyroidism: a prospective study. Arch Med Res 2013; 44(4): 317–320. Dostupné z DOI: <http://doi 10.1016/j.arcmed.2013.04.010>.
  21. Soriguer F, Valdes S, Morcillo S et al. Thyroid hormone levels predict the change in body weight: a prosp1ective study. Eur J Clin Invest 2011; 41(11): 1202–1209. Dostupné z DOI: <http://dx.doi.org/10.1111/j.1365–2362.2011.02526.x>.
  22. Ozcelik F, Yuksel C, Arslan E et al. Relationship between visceral adipose tissue and adiponectin, inflammatory markers and thyroid hormones in obese males with hepatosteatosis and insulin resistance. Arch Med Res 2013; 44(4): 273–280. Dostupné z DOI: <http://dx.doi.org/10.1016/j.arcmed.2013.04.001>.
  23. Krassas GE, Pontikides N, Loustis K et al. Resistin levels are normal in hypothyroidism and remain unchanged after attainment of euthyroidism: relationship with insulin levels and anthropometric parameters. J Endocrinol Invest 2006; 29(7): 606–612. Dostupné z DOI: <http://dx.doi.org/10.1007/BF03344159>.
  24. Ziora KT, Oswiecimska JM, Swietochowska E et al. Assessment of serum levels resistin in girls with anorexia nervosa. Part II. Relationships between serum levels of resistin and thyroid, adrenal and gonadal hormones. Neuro Endocrinol Lett 2011; 32(5): 697–703.
  25. Caixàs A, Tirado R, Vendrell J et al. Plasma visfatin concentrations increase in both hyper and hypothyroid subjects after normalization of thyroid function and are not related to insulin resistance, anthropometric or inflammatory parameters. Clin Endocrinol (Oxf) 2009; 71(5): 733–738. Dostupné z DOI: <http://dx.doi.org/10.1111/j.1365–2265.2009.03546.x>.
  26. Han J, Zhang TO, Xiao WH et al. Up-regulation of visfatin expression in subjects with hyperthyroidism and hypothyroidism is partially relevant to a nonlinear regulation mechanism between visfatin and tri-iodothyronine with various concentrations. Chin Med J (Engl) 2012; 125(5): 874–881.
  27. Guzel S, Seven A, Guzel EC et al. Visfatin, Leptin, and TNF-α: Interrelated Adipokines in Insulin-Resistant Clinical and Subclinical Hypothyroidism. Endocr Res 2013; 38(3):184–194. Dostupné z DOI: <http://dx.doi.org/10.3109/07435800.2012.760588>.
  28. Ozkaya M, Sahin M, Cakal E et al. Visfatin plasma concentrations in patients with hyperthyroidism and hypothyroidism before and after control of thyroid function. J Endocrinol Invest 2009; 32(5): 435–439. Dostupné z DOI: <http://dx.doi.org/10.3275/6296>.
Labels
Diabetology Obesitology

Article was published in

Diabetes and obesity

Issue 38

2019 Issue 38

Most read in this issue
Topics Journals
Login
Forgotten password

Enter the email address that you registered with. We will send you instructions on how to set a new password.

Login

Don‘t have an account?  Create new account

#ADS_BOTTOM_SCRIPTS#